Inflammatory Bowel Disease (IBD) remains an incurable condition, posing significant challenges for both patients and healthcare providers. Achieving and maintaining remission is the primary objective, as flare-ups can worsen over time. For paediatric patients, these challenges are further compounded by their developing bodies and the long-term implications of their treatment plans.